Interface Biosciences

Recent Finacing

Seed

Recent Raise

$3M

Interface Biosciences uses AI and metabolomics to discover bacterial natural products and develop peptide therapeutics, including a 44‑amino‑acid Ruminococcus gnavus peptide for inflammatory and infectious indications.

Founded 2020

California, United States

1-10

Private

interface.bio

Highlights

Focus Areas

Biotechnology

Health Care

Therapeutics

Recent Investors

Financials

$3M

Total Raised

1

Funding round

7

Investors

Team

Upgrade to view the team

See the team members at Interface Biosciences.